The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed. In the trial, volunteers were randomized to receive up to nine doses of Keytruda plus the personalized vaccine or Keytruda alone for about one year.
November 2, 2026 at 5:08 PM
The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed. In the trial, volunteers were randomized to receive up to nine doses of Keytruda plus the personalized vaccine or Keytruda alone for about one year.
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
November 2, 2026 at 5:02 PM
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
The treatment combines Merck's Keytruda with a made-to-order mRNA vaccine from Moderna that is based on an analysis of mutations found in the patients' own tumors.
November 2, 2026 at 5:07 PM
The treatment combines Merck's Keytruda with a made-to-order mRNA vaccine from Moderna that is based on an analysis of mutations found in the patients' own tumors.
The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Keytruda, which helps the body attack the cancer more effectively.
November 2, 2026 at 5:10 PM
The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Keytruda, which helps the body attack the cancer more effectively.
The melanoma vaccines were in development before the COVID-19 pandemic, but the research builds on the significant advances made in mRNA technology over the last six years. The trial was funded by Moderna and a subsidiary of Merck, which makes Keytruda.
November 2, 2026 at 5:10 PM
The melanoma vaccines were in development before the COVID-19 pandemic, but the research builds on the significant advances made in mRNA technology over the last six years. The trial was funded by Moderna and a subsidiary of Merck, which makes Keytruda.
Another mRNA win!💉🧬
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
GOOD NEWS! A personalized mRNA vaccine, known as mRNA-1457, has SUCCEEDED in keeping melanoma, a deadly skin cancer, from returning. Phase III clinical trial results in MORE THAN 1,100 patients shows the vaccine SIGNIFICANTLY cut the risk of death OR recurrence of melanoma by ALMOST HALF.
Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.
www.washingtonpost.com
November 2, 2026 at 5:13 PM
Another mRNA win!💉🧬
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
Merck's subcutaneous Keytruda hits $830 million in a quarter
Keytruda Qlex uses Alteogen's enzyme technology. Sales rose 79% from the prior quarter.
https://www.mt.co.kr/en/thebio/2026/11/02/2026110209174788761
Keytruda Qlex uses Alteogen's enzyme technology. Sales rose 79% from the prior quarter.
https://www.mt.co.kr/en/thebio/2026/11/02/2026110209174788761
Alteogen's Keytruda SC sales reach 1.1 trillion won as MSD seeks to accelerate global growth - MoneyToday
Jeon Tae-yeon, CEO of Alteogen. / MoneyToday photo by Jung Ki-jong Prescriptions for Alteogen's Keytruda SC (Keytruda Qlex) are on the rise. U.S.-based Merck (MSD), the developer of Keytruda,
www.mt.co.kr
November 3, 2026 at 5:14 AM
Merck's subcutaneous Keytruda hits $830 million in a quarter
Keytruda Qlex uses Alteogen's enzyme technology. Sales rose 79% from the prior quarter.
https://www.mt.co.kr/en/thebio/2026/11/02/2026110209174788761
Keytruda Qlex uses Alteogen's enzyme technology. Sales rose 79% from the prior quarter.
https://www.mt.co.kr/en/thebio/2026/11/02/2026110209174788761
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
cnb.cx
October 29, 2026 at 10:35 AM
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
The results, based on patient data for the first two years after treatment, were presented at the European Society for Medical Oncology meeting in Madrid.
• www.statnews.com/2026/10/22/e...
• www.statnews.com/2026/10/22/e...
November 2, 2026 at 5:04 PM
The results, based on patient data for the first two years after treatment, were presented at the European Society for Medical Oncology meeting in Madrid.
• www.statnews.com/2026/10/22/e...
• www.statnews.com/2026/10/22/e...
Genuinely good news. One detail makes it more impressive: everyone in the trial got Keytruda and the comparison group got a placebo shot, so "almost half" comes on top of an already strong drug.
November 3, 2026 at 6:31 AM
Genuinely good news. One detail makes it more impressive: everyone in the trial got Keytruda and the comparison group got a placebo shot, so "almost half" comes on top of an already strong drug.
Keytruda Market Size, Share, Trends | Industry Growth 2035 www.marketresearchfuture.com/reports/keyt...
Keytruda Market Size, Share, Trends | Industry Growth 2035
Global Keytruda Market size is projected to reach USD 41.72 billion by 2035 from USD 31.58 billion in 2026, at a CAGR of 3.15% during the forecast 2026–2035.
www.marketresearchfuture.com
November 2, 2026 at 8:09 AM
Keytruda Market Size, Share, Trends | Industry Growth 2035 www.marketresearchfuture.com/reports/keyt...
UK Keytruda Market Size, Growth Analysis, Outlook 2035 www.marketresearchfuture.com/reports/uk-k...
UK Keytruda Market Size, Growth Analysis, Outlook 2035
UK Keytruda Market growth is projected to reach 3.1 USD billion, at a 10.658% CAGR by driving size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.
www.marketresearchfuture.com
November 2, 2026 at 8:10 AM
UK Keytruda Market Size, Growth Analysis, Outlook 2035 www.marketresearchfuture.com/reports/uk-k...
Germany Keytruda Market Size, Growth Analysis, Outlook 2035 www.marketresearchfuture.com/reports/germ...
Germany Keytruda Market Size, Growth Analysis, Outlook 2035
Germany Keytruda Market growth is projected to reach 4.5 USD billion, at a 10.503% CAGR by driving size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.
www.marketresearchfuture.com
November 2, 2026 at 8:09 AM
Germany Keytruda Market Size, Growth Analysis, Outlook 2035 www.marketresearchfuture.com/reports/germ...
Keytruda, Han Solo
October 28, 2026 at 2:52 AM
Keytruda, Han Solo
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine Gardasil.
Merck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine Gardasil.
reut.rs
October 29, 2026 at 10:40 AM
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine Gardasil.
open.substack.com/chat/posts/f...
CORRUPT AF🤬
CORRUPT AF🤬
Uncomfortable Truth by Monica in Blue Dot Bulletin
The day the Senate voted to delay Medicare price negotiation on blockbuster cancer drugs, Trump's portfolio bought up to $950,000 in the companies that make them. Patients on Keytruda got an estimated...
open.substack.com
November 2, 2026 at 1:10 PM
open.substack.com/chat/posts/f...
CORRUPT AF🤬
CORRUPT AF🤬
With Keytruda. A very important detail people keep missing.
October 28, 2026 at 2:16 PM
With Keytruda. A very important detail people keep missing.
Cancer research! We got 2 additional years with my dad because of the Keytruda trials, when his original prognosis was only 4-5 months. I know and love so many people who are alive because of all the advances made in the past decade alone!
Well worth celebrating! (And funding.)
Well worth celebrating! (And funding.)
Social media loves talking about how everything is getting worse. But what’s something that you’ve seen get _better_ in your lifetime?
October 29, 2026 at 1:24 AM
Cancer research! We got 2 additional years with my dad because of the Keytruda trials, when his original prognosis was only 4-5 months. I know and love so many people who are alive because of all the advances made in the past decade alone!
Well worth celebrating! (And funding.)
Well worth celebrating! (And funding.)
2026. KEYTRUDA/KEYTRUDA QLEX facturó 8.600 M (+6% interanual).
October 29, 2026 at 12:51 PM
2026. KEYTRUDA/KEYTRUDA QLEX facturó 8.600 M (+6% interanual).
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Follow us on Qevra Buzz, the new social platform
#BreakingNews #Markets #BusinessNews
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Follow us on Qevra Buzz, the new social platform
#BreakingNews #Markets #BusinessNews
October 29, 2026 at 1:37 PM
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Follow us on Qevra Buzz, the new social platform
#BreakingNews #Markets #BusinessNews
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Follow us on Qevra Buzz, the new social platform
#BreakingNews #Markets #BusinessNews
#$MRK beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook. notreload.xyz/xy/merck-top...
Merck Tops Q3 Estimates as Keytruda, Gardasil Drive Growth
Merck beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook.
notreload.xyz
October 29, 2026 at 12:26 PM
#$MRK beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook. notreload.xyz/xy/merck-top...
Wow!
Keytruda as not available for lung cancer when I was diagnosed the first time.
I can understand the quality of life concerns. It is a roll of the dice.
Keytruda as not available for lung cancer when I was diagnosed the first time.
I can understand the quality of life concerns. It is a roll of the dice.
October 31, 2026 at 5:32 AM
Wow!
Keytruda as not available for lung cancer when I was diagnosed the first time.
I can understand the quality of life concerns. It is a roll of the dice.
Keytruda as not available for lung cancer when I was diagnosed the first time.
I can understand the quality of life concerns. It is a roll of the dice.
2026. KEYTRUDA/KEYTRUDA QLEX facturó 8.600 M (+6% interanual).
October 29, 2026 at 12:51 PM
2026. KEYTRUDA/KEYTRUDA QLEX facturó 8.600 M (+6% interanual).
→ What they did
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
November 2, 2026 at 6:00 PM
→ What they did
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
The FDA accepted FYB206 for potential approval in Q3 2027, yet branded manufacturers leverage PBM deals to maintain market dominance.
#Biosimilars #Keytruda #FDA
#Biosimilars #Keytruda #FDA
FDA approved FYB206 by Q3 2027
Source: BioPharma Dive
realfeedapp.com
November 2, 2026 at 6:00 PM
The FDA accepted FYB206 for potential approval in Q3 2027, yet branded manufacturers leverage PBM deals to maintain market dominance.
#Biosimilars #Keytruda #FDA
#Biosimilars #Keytruda #FDA